Valuation: Insmed Incorporated

Market Cap 28.05B 24.23B 22.8B 20.72B 38.97B 2,688B 39.54B 267B 105B 1,344B 105B 103B 4,478B P/E 2026 *
-81.2x
P/E 2027 * 126x
Enterprise Value 27.42B 23.68B 22.28B 20.25B 38.09B 2,627B 38.65B 261B 102B 1,314B 103B 101B 4,377B EV / Sales 2026 *
15.2x
EV / Sales 2027 * 9.38x
Free-Float
99.49%
Yield 2026 *
-
Yield 2027 * -
1 day+0.11%
1 week-3.10%
Current month+30.28%
1 month+18.59%
3 months+19.89%
6 months-14.99%
Current year-26.19%
1 week 122.21
Extreme 122.21
133.16
1 month 96.42
Extreme 96.42
137.7
Current year 90.39
Extreme 90.39
186.19
1 year 90.39
Extreme 90.39
212.75
3 years 21.21
Extreme 21.21
212.75
5 years 16.04
Extreme 16.04
212.75
10 years 10.21
Extreme 10.21
212.75
Manager TitleAgeSince
Chief Executive Officer 57 2012-09-09
Director of Finance/CFO 45 2020-01-30
Chief Tech/Sci/R&D Officer 62 2019-12-18
Director TitleAgeSince
Chairman 75 2009-06-15
Chairman 57 2018-11-07
Director/Board Member 72 2014-05-28
Date Insider Type Main position Quantity % Market Cap.
8/10/26 Fiscal year

Chief Operating Officer

719,550 0.3320%
8/6/26 Fiscal year

Chief Technology Officer

81,519 0.0376%
7/23/26 Fiscal year

Chief Executive Officer

32,100 0.0148%
Change 5-day change 1-year change 3-year change Capi.($)
+0.11%-3.10%+0.94%+491.16% 28.02B
+0.17%+4.35%+72.39%+114.97% 73.25B
+1.73%+16.15%+51.73%+93.89% 61.95B
-1.73%+4.42%+60.24%+19.90% 24.15B
+1.26%-0.05%-17.59%-15.96% 23.01B
0.00%+5.57%+39.57%-14.30% 19.46B
-0.71%-4.11%+243.99%+423.83% 18.35B
-3.32%-1.14%+14.58%+514.71% 15.92B
+1.53%+3.49%+40.68%+151.75% 12.96B
-0.90%-1.50%+341.49%+211.04% 12.53B
Average -0.23%+2.19%+84.80%+199.10% 28.96B
Weighted average by Cap. +0.16%+4.68%+68.60%+167.19%

Financials

2026 *2027 *
Net sales 1.81B 1.56B 1.47B 1.33B 2.51B 173B 2.55B 17.22B 6.75B 86.56B 6.78B 6.63B 288B 2.87B 2.48B 2.33B 2.12B 3.98B 275B 4.04B 27.33B 10.71B 137B 10.77B 10.53B 458B
Net income -341M -294M -277M -252M -473M -32.65B -480M -3.25B -1.27B -16.33B -1.28B -1.25B -54.4B 204M 176M 166M 151M 283M 19.53B 287M 1.94B 761M 9.77B 765M 749M 32.53B
Net Debt -632M -546M -513M -467M -878M -60.54B -891M -6.02B -2.36B -30.28B -2.37B -2.32B -101B -1.16B -999M -940M -854M -1.61B -111B -1.63B -11.03B -4.32B -55.43B -4.34B -4.25B -185B
Logo Insmed Incorporated
Insmed Incorporated specializes in the research and development of drugs for the treatment of respiratory, immunological, inflammatory, neurological, and rare diseases. At the end of 2025, the group has two products in the commercialization phase: ARIKAYCE® for the treatment of lung infection caused by the Mycobacterium avium complex and BRINSUPRI® for the treatment of bronchiectasis (dilation of the bronchi) unrelated to cystic fibrosis. The United States account for 74.7% of net sales.
Employees
1,664
Date Price Change Volume
26-08-18 US$128.46 +0.11% 1,274,080
26-08-17 US$128.32 +3.70% 1,899,670
26-08-14 US$123.74 -2.05% 1,957,324
26-08-13 US$126.33 -4.50% 2,479,563
26-08-12 US$132.28 -0.22% 1,563,224
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
A
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
128.46USD
Average target price
200.05USD
Spread / Average Target
+55.73%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. INSM Stock